2 results
Approved WMOCompleted
Part A - CX-2009 Monotherapy: Every 21-Day Dosing RegimenThe primary objective of Part A is to determine the safety profile of CX-2009, the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the dose-limiting toxicities(DLTs) of CX-…
Not approvedWill not start
Objective:The objective of the study is to test the hypothesis that the QWHET micro current wound stimulation device has minimal side effects. The study will be designed as a double blind, prospective study.The results will be used to obtain a CE…